Dr. Anees Arshad MD

Recommended Articles

• What is Acute Respiratory Distress Syndrome?

  Acute respiratory distress syndrome, or ARDS, the malignant inflammation of the lungs, and develops as a response to an infection or infection. Recently, our understanding of the pathophysiology of this condition has improved a lot and has led to better medical interventions. Since this is one of...

• Pleurisy vs. Bronchitis: Differences and Similarities

  What is pleurisy?Pleurisy is a condition, in which the lining that surrounds the lungs and the interior of the chest cavity is inflamed. Due to the inflammation of the pleura, this condition is also called as pleuritis. The pleural space is the space between the lungs and the chest cavity wall....

• Chronic Bronchitis – The Smoker’s Cough

  What is chronic bronchitis?Chronic bronchitis is defined as a persistent cough with sputum production for at least three months in at least two consecutive years in the absence of any other identifiable causes.Chronic bronchitis is also commonly known as the smoker’s cough. This is due to the fact...

• Different Types of Physicians Explained

  Doctors or physicians are categorized according to different factors including medical specialties and subspecialties. Most doctors specialize in a specific area of medicine. This article provides a summary of the different types of doctors in the medical field. AllergistsAllergists are also...

• Atelectasis vs Pneumothorax: What’s the Difference?

  What Is Atelectasis?Atelectasis is a complete or partial collapse of the lung or lobe of a lung. This medical condition develops when the tiny sacs, known as alveoli, present within the lung become deflated.This is a breathing complication which often occurs after surgery. Apart from surgery, it is...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...